Palbociclib Doubles Survival in Women with Advanced Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published online today in the journal The Lancet Oncology, researchers from Jonsson Comprehensive Cancer Center in Los Angeles, California, have found that palbociclib doubled progression-free survival in women with advanced breast cancer compared with those who did not receive the drug.
For the phase 2 study, researchers enrolled 165 post-menopausal women with advanced estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Patients received letrozole with or without palbociclib.
Results showed that progression-free survival was 20.2 months in the letrozole plus palbociclib arm versus 10.2 months in the letrozole only arm, corresponding with a 51% decreased risk of disease progression with palbociclib.
Furthermore, over 80% of those with metastatic estrogen receptor-positive disease experienced some benefit from the addition of palbociclib. In regard to safety, palbociclib caused leukopenia, but only to a manageable extent. Palbociclib prevents cancer cell proliferation by targeting CDK4/6 proteins, which are responsible for cell growth.
Palbociclib was granted Breakthrough Therapy Designation in 2013 by the U.S. Food and Drug Administration (FDA), and researchers are currently conducting an international phase 3 study in conjunction with Pfizer of palbociclib in 660 estrogen receptor-positive, HER2-negative advanced breast cancer.
Palbociclib doubled PFS in women with ER-positive, HER2-positive advanced breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Identifying Molecular Determinants of Response to Apalutamide
- Immunotherapy in Glioblastoma: Peaks and Pits
- Bladder Cancer Response to Bacillus Calmette-Guérin May Be Linked to Urine Microbiome
- Investigational Antiandrogen Drug Delays Metastasis in CPRC
- Clinical Applications of Liquid Biopsies in Cancer